Vuzix Corporation (VUZI) Stock: A Closer Look at the Analyst Ratings
Additionally, the 36-month beta value for VUZI is 1.44. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0
Additionally, the 36-month beta value for VUZI is 1.44. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0
CytomX Therapeutics Inc (NASDAQ: CTMX)’s stock price has gone rise by 2.50% in comparison to its previous close of $2.4, however, the company has experienced
The stock of Equillium Inc (EQ) has gone up by 12.44% for the week, with a -6.79% drop in the past month and a -21.50%
The stock has a 36-month beta value of 3.26. The public float for HOLO is 4.62M, and at present, short sellers hold a 23.79% of
The stock of Soleno Therapeutics Inc (NASDAQ: SLNO) has increased by 4.97% when compared to last closing price of $85.26. Despite this, the company has
In the past week, NAMS stock has gone up by 16.05%, with a monthly gain of 4.99% and a quarterly surge of 33.32%. The volatility
The 36-month beta value for IE is also noteworthy at 0.87. There are mixed opinions on the stock, with 2 analysts rating it as a
The stock of Boyd Gaming Corp (NYSE: BYD) has increased by 2.56% when compared to last closing price of $81.33.Despite this, the company has seen
The stock of Standard BioTools Inc (LAB) has seen a 3.88% increase in the past week, with a 26.42% gain in the past month, and
Company’s 36-month beta value is 0.48.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as
© 2024, Powered by Smart TechOne